Zenas BioPharma: FDA Accepts Obexelimab BLA, CFO Transition, Q2 Loss Widens

summarizeSummary

Zenas BioPharma announced FDA acceptance of its obexelimab BLA for IgG4-RD, a CFO transition, and Q2 2026 financial results showing a wider net loss.

check_boxKey Events · Earnings and Guidance · ZBIO

• FDA Accepts Obexelimab BLA

  FDA accepted the BLA for obexelimab for IgG4-RD with a PDUFA target action date of May 27, 2027. This is the company's first regulatory submission for its lead product candidate.

• CFO Transition Announced

  Jennifer Fox will transition from CFO and Chief Business Officer to Strategic Advisor to the Board Chair effective September 30, 2026. Joe Farmer, President and COO, will serve as Principal Financial Officer until a new CFO is appointed.

• Q2 2026 Net Loss Widens

  Net loss was $111.5 million for Q2 2026, compared to $52.2 million in Q2 2025. The increase was driven by higher R&D expenses ($62.9M vs $43.0M), a $30.0M acquired in-process R&D charge, and increased interest expense.

• Cash Runway Extended

  Cash, cash equivalents and investments totaled $673.9 million as of June 30, 2026. Combined with expected milestone payments and ATM proceeds, the company expects to fund operations at least through Q2 2029.

auto_awesomeAnalysis · ZBIO · Life Sciences

The FDA acceptance of the obexelimab BLA with a PDUFA date of May 27, 2027 is a major regulatory milestone that moves the company closer to its first commercial product. The CFO transition adds leadership uncertainty, while the Q2 net loss of $111.5 million reflects increased R&D and milestone expenses. The company's cash position of $673.9 million provides runway into 2029, but the loss trajectory and upcoming data readouts will be key drivers.